Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Millennium Partners has called for International Biotechnology Trust to be wound up and assets returned to shareholders. Millennium (New York, N.Y.), a 10 percent shareholder, has called for
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury